Startseite>>Signaling Pathways>> Stem Cell>> Wnt/β-catenin>>NSC 668036

NSC 668036

Katalog-Nr.GC44467

NSC 668036 ist ein Inhibitor der Disheveled (Dvl)-PDZ-Domäne mit einer Kd von 237 \u0026mgr;M.

Products are for research use only. Not for human use. We do not sell to patients.

NSC 668036 Chemische Struktur

Cas No.: 144678-63-7

Größe Preis Lagerbestand Menge
1mg
49,00 $
Auf Lager
5mg
161,00 $
Auf Lager
10mg
248,00 $
Auf Lager
25mg
558,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

NSC 668036 is an inhibitor of the Dishevelled (Dvl) protein PDZ domain (Kd = 240 μM for mouse Dvl1 PDZ domain). NSC 668036 interacts with Dvl PDZ at the same binding site as Dapper and Frizzled, native binding partners in the Wnt signaling pathway. NSC 668036 (180 ng) reduces expression of the Wnt target gene, Siamois, in Xenopus embryos and inhibits the ability of injected Wnt3A to induce formation of a secondary axis. At concentrations greater than 10 μM, NSC 668036 inhibits proliferation of NIH/3T3 fibroblasts, restrains their migration in a scratch assay, and blocks the accelerating effect of TGF-β on fibroblast migration. NSC 668036 (5 mg/kg per day for 14 days) reduces the severity of pulmonary fibrosis in mice by bleomycin . NSC 668036 also blocks the bleomycin-induced pulmonary expression of α-smooth muscle actin (α-SMA), collagen I, TGF-β, and β-catenin by 30-50%.

Bewertungen

Review for NSC 668036

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for NSC 668036

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.